Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Launches Warrant Exercise Incentive Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has launched an early-exercise warrant incentive program intended to encourage the early exercise of up to 7.8 million of its outstanding unlisted warrants.

The Winnipeg, Manitoba-based firm said that the warrants entitle holders to acquire one share of common stock at a price of C$.10 (US$.10) until June 17, 2011. The warrant holders are now being offered an incentive consisting of a half warrant in addition to the common share issuable for each warrant.

The incentive warrant is exercisable for one common share at a price of C$.18 until Dec. 15, 2011.

The firm said that the current warrant holders would need to exercise this option between Feb. 16 and ending 5:00 PM (Winnipeg time) on March 8. Only warrant holders that exercise all of their remaining warrants during the early exercise period will be eligible to receive the incentive warrants.

If all warrants are exercised on or before expiration of the early exercise period, Miraculins expects to receive gross proceeds of around C$780,000, issue 7.8 million common shares, and issue 3.9 million incentive warrants.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.